Mr. Daniel D. Burgess is a Chairman at Nabriva Therapeutics Plc, an Independent Director at Cidara Therapeutics, Inc., a Venture Partner at SV Health Investors LLC, a Chairman at AtoxBio, Inc., a Chairman at BIOCOM and a Chairman at Pulmocide Ltd.
He is on the Board of Directors at Arbutus Biopharma Corp., Cidara Therapeutics, Inc. and Leiter's Enterprises, Inc.
Mr. Burgess was previously employed as a Chairman-Supervisory Board by Nabriva Therapeutics AG, a President, Chief Executive Officer & Director by Rempex Pharmaceuticals, Inc., a President & Chief Executive Officer by Mpex Pharmaceuticals, Inc., an Independent Director by Santarus, Inc., a Chief Financial & Operating Officer by Harbor BioSciences, Inc., a Chief Financial Officer & Vice President by Nanogen, Inc., a Principal by Castle & Cooke, Inc., a President by Gensia Automedics, Inc., a Chief Financial Officer & Vice President by SICOR, Inc., and a Financial Analyst by Smith Barney Harris Upham & Co., Inc.
He also served on the board at Metabasis Therapeutics, Inc., Arsanis, Inc. and Genoa Pharmaceuticals, Inc.
He received his undergraduate degree from Stanford University and an MBA from Harvard Business School.